Adamas Pharmaceuticals, Inc (ADMS)

Etorro trading 970x250
Adamas Pharmaceuticals, Inc (ADMS) Logo

About Adamas Pharmaceuticals, Inc

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Address: 1900 Powell Street, EmeryVille, CA, United States, 94608

Adamas Pharmaceuticals, Inc News and around…

Latest news about Adamas Pharmaceuticals, Inc (ADMS) common stock and company :

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm
22 Oct, 2021 FinancialContent
Why Supernus' Acquisition of Adamas Is a Smart Move
21 Oct, 2021 FinancialContent

Adamas looks like a good fit for Supernus.

Lifshitz Law Firm, P.C. Announces Investigation of ADMS, ACBI, FLXN, and HBMD
21 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS owned. If you are an investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KRA, EBMT, ESBK, ADMS; Shareholders are Encouraged to Contact the Firm
20 Oct, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
19 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. (NASDAQ:ADMS)Agreement Announcement: October 11, 2021 Transaction Details:Upon the closing of the transaction, Supernus will acquire Adamas through a tender offer for $8.

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
18 Oct, 2021 Yahoo! Finance

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, AZPN, GSKY, GWB; Shareholders are Encouraged to Contact the Firm
18 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash. If you are an Adamas share

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS
16 Oct, 2021 Yahoo! Finance

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Adamas Pharmaceuticals, Inc. ("ADMS" or the "Company") (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights col

Rockville biotech banks on new revenue with $450M acquisition of a West Coast drugmaker
15 Oct, 2021 Yahoo! Finance

The deal creates some immediate and long-term opportunities for Supernus, which focuses on central nervous system diseases.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm
15 Oct, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

ADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the Firm
14 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Click here to learn more and participate in the action. On October 12, 2021, Adamas announc

10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
14 Oct, 2021 Yahoo! Finance

In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Adamas Pharmaceuticals, Inc. (Nasdaq - ADMS)
13 Oct, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / October 13, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors ofAdamas Pharmaceuticals, Inc. ("Adamas Pharmaceuticals" or the "Company") (NASDAQ:ADMS) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Supernus Pharmaceuticals, Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the Firm
12 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash. If you are an Adamas share

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Adamas Pharmaceuticals, Inc. Merger
12 Oct, 2021 Yahoo! Finance

WILMINGTON, Del., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) (NASDAQ GM: ADMS) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus Pharmaceuticals, Inc. (NASDAQ GM: SUPN). Under the terms of the agreement, Adamas’ shareholders will receive $8.10 in cash and two non-tradeable contingent value rights collectively worth up to $1.00 per

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. -
12 Oct, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain conditions are met) for each share of Adamas that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS
12 Oct, 2021 Yahoo! Finance

NEW ORLEANS, October 12, 2021--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain

ADMS Crosses Above Average Analyst Target
12 Oct, 2021 FinancialContent

In recent trading, shares of Adamas Pharmaceuticals Inc (ADMS) have crossed above the average analyst 12-month target price of $7.92, changing hands for $8.07/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct, 2021 FinancialContent

Upgrades For Callaway Golf Co (NYSE:ELY), Compass Point upgraded the previous rating of Neutral to Buy. Callaway Golf earned $0.36 in ...

46 Biggest Movers From Yesterday
12 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full ...

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
11 Oct, 2021 FinancialContent

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened in the markets thus far.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Adamas Pharmaceuticals, Inc. with Supernus Pharmaceuticals, Inc.
11 Oct, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/99237_49c2a1d4a49d6a28_001full.jpgYou are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fair

Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus
11 Oct, 2021 Yahoo! Finance

Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus.

12 Health Care Stocks Moving In Monday's Intraday Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. ...

Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
11 Oct, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, ...

28 Stocks Moving In Monday's Mid-Day Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on ...

ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
11 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS
11 Oct, 2021 FinancialContent

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders.

Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
11 Oct, 2021 FinancialContent

Supernus Pharmaceuticals Inc(NASDAQ: SUPN)has agreed to acquireAdamas Pharmaceuticals Inc(NASDAQ: ADMS) for ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The ...

Adamas Pharmaceuticals, Inc (ADMS) is a NASDAQ Common Stock listed in , ,

970x250